SCOPUS 정보 검색 플랫폼

Expert Opinion on Therapeutic Targets

Volumn 13, Issue 2, 2009, Pages 139-140

Bilirubin and peripheral arterial disease: 15 Years later

(2) Breimer, Lars H a Mikhailidis, Dimitri P b

a ÖREBRO UNIVERSITY HOSPITAL (Sweden)

b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL (United Kingdom)

Author keywords

Bilirubin; Free radicals; Innsbruck; NHANES; PAD (peripheral arterial disease); Smoking

Indexed keywords

BILIRUBIN;

ARTERY DISEASE; BILIRUBIN BLOOD LEVEL; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; COHORT ANALYSIS; HUMAN; ISCHEMIC HEART DISEASE; RETROSPECTIVE STUDY; REVIEW; SERUM; SEX DIFFERENCE; BLOOD; CLINICAL TRIAL; EDITORIAL; FEMALE; HEART MUSCLE ISCHEMIA; MALE; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; RISK FACTOR;

BILIRUBIN; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MYOCARDIAL ISCHEMIA; PERIPHERAL VASCULAR DISEASES; RISK FACTORS;

EID: 64349091503 PISSN: 14728222 EISSN: None Source Type: Journal
DOI: 10.1517/14728220802655321 Document Type: Review

Times cited : (8)

References (11)

1
- 37549065092
- Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease
- Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease. Arterioscl Thromb Vascul Biol 2008;28:166-172
- (2008) Arterioscl Thromb Vascul Biol , vol.28 , pp. 166-172
- Perlstein, T.S.¹ Pande, R.L.² Beckman, J.A.³ Creager, M.A.⁴

2
- 43449118699
- Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: Results from the CAVASIC study
- DOI 10.1373/clinchem.2007.102046
- Rantner B, Kollertis B, Anderwald-Stadler M, et al. Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study. Clin Chem 2008;54:851-857 (Pubitemid 351671602)
- (2008) Clinical Chemistry , vol.54 , Issue.5 , pp. 851-857
- Rantner, B.¹ Kollerits, B.² Anderwald-Stadler, M.³ Klein-Weigel, P.⁴ Gruber, I.⁵ Gehringer, A.⁶ Haak, M.⁷ Schnapka-Kopf, M.⁸ Fraedrich, G.⁹ Kronenberg, F.¹⁰

3
- 0028148503
- Is bilirubin protective against coronary artery disease?
- Breimer LH, Spyropolous KA, Winder AF, et al. Is bilirubin protective against coronary artery disease? Clin Chem 1994;40:1987-1988
- (1994) Clin Chem , vol.40 , pp. 1987-1988
- Breimer, L.H.¹ Spyropolous, K.A.² Winder, A.F.³

4
- 0035130493
- High serum bilirubin level is inversely associated with the presence of carotid plaque [3]
- Ishizaka N, Ishizaka Y, Takahashi E, et al. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke 2001;32:580-583 (Pubitemid 32155258)
- (2001) Stroke , vol.32 , Issue.2 , pp. 581-583
- Ishizaka, N.¹ Ishizaka, Y.² Takahashi, E.³ Yamakado, M.⁴ Hashimoto, H.⁵

5
- 49949108687
- Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004
- Perlstein TS, Pande RL, Creager MA, et al. Serum total bilirubin level, prevalent stroke, and stroke outcomes: NHANES 1999-2004. Am J Med 2008;121:781-788
- (2008) Am J Med , vol.121 , pp. 781-788
- Perlstein, T.S.¹ Pande, R.L.² Creager, M.A.³

6
- 0036228452
- The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: Bilirubin and albumin
- Krijgsman B, Papadakis JA, Ganotakis ES, et al. The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin. Int Angiol 2002;21:44-52 (Pubitemid 34413653)
- (2002) International Angiology , vol.21 , Issue.1 , pp. 44-52
- Krijgsman, B.¹ Papadakis, J.A.² Ganotakis, E.S.³ Mikhailidis, D.P.⁴ Hamilton, G.⁵

7
- 0033000175
- Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia
- DOI 10.1016/S0895-7061(99)00049-7, PII S0895706199000497
- Papadakis JA, Ganotakis ES, Jagroop IA, et al. Effect of hypertension and its treatment on lipid, lipoprotein (a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999;12:673-681 (Pubitemid 29322839)
- (1999) American Journal of Hypertension , vol.12 , Issue.7 , pp. 673-681
- Papadakis, J.A.¹ Ganotakis, E.S.² Jagroop, I.A.³ Mikhailidis, D.P.⁴ Winder, A.F.⁵

8
- 34547732921
- Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation
- Ganotakis ES, Vrentzos GE, Gazi IF, et al. Fibrinogen, lipoprotein (a), albumin and bilirubin (F-L-A-B) levels and cardiovascular risk calculated using the Framingham equation. In Vivo 2007;2:685-694 (Pubitemid 47232673)
- (2007) In Vivo , vol.21 , Issue.4 , pp. 685-694
- Ganotakis, E.S.¹ Vrentzos, G.E.² Gazi, I.F.³ Papadakis, J.A.⁴ Jagroop, I.A.⁵ Paraskevas, K.I.⁶ Nair, D.R.⁷ Mikhailidis, D.P.⁸

9
- 0028084319
- Association of low serum concentration of bilirubin with increased risk of coronary artery disease
- Schwertner HA, Jackson WG, Tolan G. Association of low serum concentration of bilirubin with increased risk of coronary artery disease. Clin Chem 1994;40:18-23 (Pubitemid 24050206)
- (1994) Clinical Chemistry , vol.40 , Issue.1 , pp. 18-23
- Schwertner, H.A.¹ Jackson, W.G.² Tolan, G.³

10
- 33845613215
- The Heme Catabolic Pathway and its Protective Effects on Oxidative Stress-Mediated Diseases
- DOI 10.1016/S0065-2423(06)43001-8, PII S0065242306430018
- Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv Clin Chem 2007;43:1-57 (Pubitemid 44960959)
- (2007) Advances in Clinical Chemistry , vol.43 , pp. 1-57
- Vitek, L.¹ Schwertner, H.A.²

11
- 0003945589
- Burtis CA, Ashwood ER, editors, WB Saunders & Co; Philadelphia, PA, USA
- Burtis CA, Ashwood ER, editors, Tietz Textbook of Clinical Chemistry, 3rd edition. WB Saunders & Co; Philadelphia, PA, USA; 1999
- (1999) Tietz Textbook of Clinical Chemistry, 3rd Edition

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.